aFutures Institute, Glastonbury, Connecticut bCenter for Health Decision Science, Harvard School of Public Health cDepartment of Global Health and Population, Harvard School of Public Health dDivision of Global Health Equity, Brigham and Women's Hospital eDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA fMRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology gDepartment of Infectious Disease Epidemiology, Imperial College London hDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. *Carel Pretorius and Nicolas A. Menzies contributed equally to the writing of this article.
AIDS. 2014 Jan;28 Suppl 1:S25-34. doi: 10.1097/QAD.0000000000000085.
OBJECTIVE(S): Many countries are considering expanding HIV treatment following recent findings emphasizing the effects of antiretroviral therapy (ART) on reducing HIV transmission in addition to already established survival benefits. Given the close interaction of tuberculosis (TB) and HIV epidemics, ART expansion could have important ramifications for TB burden. Previous studies suggest a wide range of possible TB impacts following ART expansion. We used three independently developed TB-HIV models to estimate the TB-related impact of expanding ART in South Africa.
We considered two dimensions of ART expansion--improving coverage of pre-ART and ART services, and expanding CD4-based ART eligibility criteria (from CD4 <350 to CD4 <500 or all HIV-positive).
Three independent mathematical models were calibrated to the same data pertaining to the South African HIV-TB epidemic, and used to assess standardized ART policy changes. Key TB impact indicators were projected from 2014 to 2033.
Compared with current eligibility and coverage, cumulative TB incidence was projected to decline by 6-30% over the period 2014-2033 if ART eligibility were expanded to all HIV positive individuals, and by 28-37% if effective ART coverage were additionally increased to 80%. Overall, expanding ART was estimated to avert one TB case for each 10-13 additional person-years of ART. All models showed that TB incidence and mortality reductions would grow over time, but would stabilize towards the end of the projection period.
ART expansion could substantially reduce TB incidence and mortality in South Africa and could provide a platform for collaborative HIV-TB programs to effectively halt HIV-associated TB.
最近的研究结果强调了抗逆转录病毒疗法(ART)除了已确立的生存益处外,对降低 HIV 传播的影响,许多国家正在考虑扩大 HIV 治疗。鉴于结核病(TB)和 HIV 流行之间的密切相互作用,ART 扩展可能对 TB 负担产生重要影响。先前的研究表明,ART 扩展后可能会对 TB 产生广泛的影响。我们使用三个独立开发的 TB-HIV 模型来估计南非扩大 ART 对 TB 相关影响。
我们考虑了两种 ART 扩展维度——改善预 ART 和 ART 服务的覆盖范围,以及扩大 CD4 为基础的 ART 资格标准(从 CD4 <350 扩展到 CD4 <500 或所有 HIV 阳性)。
三个独立的数学模型根据南非 HIV-TB 流行的相同数据进行了校准,并用于评估标准化的 ART 政策变化。从 2014 年到 2033 年,预计关键的 TB 影响指标。
与当前的资格和覆盖范围相比,如果将 ART 资格扩大到所有 HIV 阳性个体,2014 年至 2033 年期间,预计累计 TB 发病率将下降 6-30%,如果有效 ART 覆盖率另外增加到 80%,则下降 28-37%。总的来说,扩大 ART 估计每增加 10-13 人年的 ART 就可以避免一例 TB 病例。所有模型都表明,TB 发病率和死亡率的降低将随着时间的推移而增加,但在预测期结束时趋于稳定。
在南非,扩大 ART 可以大大降低 TB 的发病率和死亡率,并为 HIV-TB 联合规划提供一个平台,以有效地阻止与 HIV 相关的 TB。